SQZ Biotechnologies (NYSE:SQZ – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.01), Fidelity Earnings reports. SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%.
SQZ Biotechnologies Stock Performance
NYSE:SQZ opened at $3.39 on Friday. The firm’s fifty day moving average is $3.25 and its 200-day moving average is $4.31. SQZ Biotechnologies has a 52 week low of $2.61 and a 52 week high of $16.17. The firm has a market cap of $95.43 million, a P/E ratio of -1.28 and a beta of 2.65.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital started coverage on shares of SQZ Biotechnologies in a research report on Wednesday, May 25th. They issued a “buy” rating and a $17.00 price target for the company.
Institutional Investors Weigh In On SQZ Biotechnologies
A hedge fund recently raised its stake in SQZ Biotechnologies stock. Charles Schwab Investment Management Inc. increased its stake in shares of SQZ Biotechnologies (NYSE:SQZ – Get Rating) by 7.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,693 shares of the company’s stock after acquiring an additional 4,196 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of SQZ Biotechnologies worth $292,000 at the end of the most recent quarter. 66.56% of the stock is currently owned by institutional investors.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
- Get a free copy of the StockNews.com research report on SQZ Biotechnologies (SQZ)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.